Company Deep Dive
Read the full research report: business segments breakdown, earnings transcripts review, management credibility analysis, competitive landscape, and scenarios.
BMY
Strong BuyAPPROVEBristol-Myers Squibb Company · Healthcare · United States · $136.0B · Avg Vol: $720M/d
Bristol-Myers Squibb is transitioning into a domestic-heavy, high-moat specialty pharma player. The recent regulatory signals (5.7% EPS consensus revision) reflect success in their clinical pipeline, notably their new myeloma treatment. As geopolitical friction forces pharma supply chains to regionalize, BMY's established U.S. manufacturing footprint serves as a strategic moat, insulating it from the cost-inflation and regulatory risks facing globalized generic drug importers.
COMPANY DESCRIPTION
Bristol-Myers Squibb Company is a global biopharmaceutical company focused on discovering, developing, manufacturing, and marketing innovative medicines for serious diseases, primarily in oncology, immunology, cardiovascular, and hematology. Its strong research and development pipeline, coupled with a portfolio of blockbuster drugs and strategic acquisitions, provides a significant competitive moat in specialized therapeutic areas. BMY is a leading global biopharmaceutical firm known for its groundbreaking therapies and robust intellectual property portfolio.
FINANCIAL SUMMARY (USD)
| Year | 2022 | 2023 | 2024 | 2025 | CAGR | TTM | 2026E | 2027E | Fwd CAGR |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 46.2B | 45.0B | 48.3B | 48.2B | 1.4% | 49.2B | 49.8B | 48.1B | -0.1% |
| EPS | 2.97 | 3.88 | -4.41 | 3.47 | 5.3% | 4.54 | 3.92 | 3.70 | 3.3% |
| Shares | 2.1B | 2.0B | 2.0B | 2.0B | -1.9% | 2.0B | — | — | — |
| Debt | 40.7B | 41.5B | 51.2B | 47.1B | 5.0% | 45.1B | — | — | — |
| Equity | 31.1B | 29.4B | 16.3B | 18.5B | -15.9% | — | — | — | — |
| Op CF | 13.1B | 13.9B | 15.2B | 14.2B | 2.7% | 12.8B | — | — | — |
| Inv CF | -1.1B | -2.3B | -21.4B | -4.1B | — | — | — | — | — |
| Fin CF | -17.0B | -9.4B | 5.1B | -10.3B | — | — | — | — | — |
SCORE BREAKDOWN
FUNDAMENTALS
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of BMY are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| BMY | Bristol-Myers Squibb Company(you) | $136.0B | 99 | Strong Buy |
| SNY | Sanofi | $107.4B | 96 | Strong Buy |
| PFIZ34.SA | Pfizer Inc. | $161.7B | 93 | Strong Buy |
| N1VO34.SA | Novo Nordisk A/S | $210.5B | 98 | Strong Buy |
| AMG.DE | Amgen Inc. | $238.5B | 93 | Strong Buy |
| GSK.L | GSK plc | $100.5B | 87 | Strong Buy |
| GILD.MX | Gilead Sciences, Inc. | $181.0B | 85 | Strong Buy |
| MRK.MX | Merck & Co., Inc. | $372.4B | 91 | Strong Buy |
| NOVN.SW | Novartis AG | $299.9B | 86 | Strong Buy |
| 4578.T | Otsuka Holdings Co., Ltd. | $40.0B | 94 | Strong Buy |
Peer medians: ROE 2.0% · P/E 24.0x · Gross margin 52.2%